Advances in Ovarian Cancer Research: From Concept to Clinic
September 18-21, 2013
J.W. Marriott Marquis Miami
Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY
David G. Huntsman, The University of British Columbia, Vancouver, BC, Canada
Sandra Orsulic, Cedars-Sinai Medical Center, Los Angeles, CA
The past decade has seen significant advances in molecular medicine and genomic science. The treatment of ovarian cancer has slowly improved due to advances in cytotoxic agents, drug delivery, and clinical care. Recent studies have expanded our understanding of the molecular etiology and pathogenesis of ovarian cancer. We now understand that ovarian cancer is not one disease but many that each has unique genomic and phenotypic origins. In order to make substantial advances in the treatment of women with ovarian cancer, based on progress made to date, these efforts need to be coordinated and orchestrated into effective clinical trials and subsequently approved treatments.
This conference featured a pre-conference educational session that not only educated attendees on how to use various cutting-edge databases, for example, mining data from the TCGA database or using Cancer Cell Line Encyclopedia (CCLE), but also discussed biomarker development and what it takes to bring a drug from development to clinic. The entire conference was designed to smoothly walk the attendees from basic concepts in ovarian cancer to high-throughput analysis to therapeutic opportunities and targeting of drug resistance. This highly comprehensive conference provided an extremely stimulating environment that furthered the scientific and translational goals of the field and allowed more effective exchanges of ideas between basic and translational scientists with clinical oncologists in order to bridge the gap between discovery and therapy.
* Adobe Acrobat Reader required
Please visit the AACR Meetings & Workshops Calendar for a complete list of upcoming programs.